Eli Lilly LLY shares are trading higher on Monday amid overall strength in the health care sector.
The company late Friday announced FDA approval for Retevmo in patients with advanced RET-driven lung and thyroid cancers.
Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; Taltz and Olumiant for immunology; and Cialis for erectile dysfunction.
Eli Lilly shares were trading up 2.46% to $157.24 at time of publication on Monday. The stock has a 52-week high of $164.90 and a 52-week low of $101.36.
Related Links:
Eli Lilly Delays New Study Starts
Eli Lilly Reports Mixed Q3 Earnings, Raises Guidance
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
